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Abstract

THE USE OF LACTOBACILLUS IN THE TREATMENT OF C. DIFFICILEASSOCIATED DIARRHEA IN HOSPITALIZED ADULT PATIENTS
By Ali Alhammad, BPharm, MS
A thesis submitted in partial fulfillment of the requirements for the degree of
Masters of Science in Pharmaceutical Sciences at Virginia Commonwealth University.

Virginia Commonwealth University, 2009

Major Director: Spencer E. Harpe, PharmD, PhD, MPH
Assistant Professor, Department of Pharmacy

Objective
To describe the use of Lactobacillus by hospitalized patients and to examine its
relationship with various Clostridium difficile infection (CDI) related outcomes.
Methods
The characteristics of Lactobacillus users and non-users and the initiation of
Lactobacillus with respect to initiation of antibiotic therapy and CDI treatment were
described using national hospital discharge database. The relationships between

x

Lactobacillus use and post-CDI length of stay, mortality, switch of CDI therapy, and
readmission were analyzed.
Results
Lactobacillus users and non-users were different in most characteristics.
Metronidazole and fluoroquinolones were the most frequently used antibiotics by
Lactobacillus users. They were mainly CDI cases, used multiple antibiotics, extremely ill,
and started Lactobacillus five or more days after initiation of antibiotics or CDI treatment.
Lactobacillus use was associated with increased length of stay and switching of CDI
therapy.
Conclusions
The true association between Lactobacillus use and CDI remains unclear. This
study provides foundation for future research.

xi

CHAPTER 1 INTRODUCTION
Background
Clostridium difficile is a gram-positive anaerobic spore-forming rod-shaped
bacteria (bacillus). C. difficile produces two potent toxins: toxin A which is an enterotoxin,
and toxin B which is a cytotoxin. Both are implicated in the pathogenesis of C. difficile
infection (CDI). They act synergistically and are capable of damaging the human colonic
epithelium.1, 2
The severity of CDI ranges from mild diarrhea to life-threatening conditions, such
as pseudomembranous colitis and toxic megacolon.3, 4 CDI is the leading identified type of
nosocomial diarrhea.5 In addition, it is implicated in 20% to 30% of patients with
antibiotic-associated diarrhea (AAD) and in more than 90% of those with antibioticassociated pseudomembranous colitis.1, 2 CDI may result in an increased length of stay by
three to seven days, as well as a 20% to 65% increase in the rate of subsequent infections.
There may also be a two- to three-fold increase in mortality as a result of CDI.6-8 In
addition to these clinical consequences, the long-term costs attributed to CDI in the United
States in 2003 were estimated to be between $897 million and $1.3 billion.1, 2, 10, 11
Current treatment strategies of CDI consist of discontinuing the offending
antibiotic, if possible, and initiating antibacterial treatment, which could be either oral
metronidazole or oral vancomycin. Unfortunately, these treatment strategies are associated
1

with a high recurrence rate of up to 28 %.6, 12 Some evidence shows that oral teicoplanin
may be a better choice than vancomycin in some cases, but this agent is not available in the
United States.13
Probiotics, defined as live microbial dietary supplements that beneficially affect the
host by improving intestinal microbial balance,15 have been used as a way of restoring
intestinal microflora. This acts as a protective barrier that resists the colonization of
intestinal pathogens and consequently decreases the incidence and duration of antibioticassociated diarrhea in general. Probiotics may also prevent CDI. They are relatively
inexpensive, generally safe and well tolerated.16
There have been several studies reported in the last three decades looking at the
effect of probiotics on the treatment of CDI.7, 8, 18-26 These studies yielded contradictory
results because of differences in study design, type and duration of probiotics therapy,
differing doses and durations of antibiotic treatment. There are different types of probiotics
that have variable efficacy in the prevention and treatment of CDI. Lactobacillus
rhamnosus GG (LGG) and Saccharomyces boulardii were shown to be more effective than
other probiotics. In addition, they have many other potential positive health effects.24, 27, 28
McFarland et al. studied the effect of adding S. boulardii to the regular treatment of
CDI. Compared to the control group, they found that the S. boulardii group was
significantly more likely to respond to antibiotic therapy and less likely to experience
recurrence of diarrhea.24 Surawicz et al. in similar study found that the high dose
vancomycin group with S. boulardii demonstrated decreased frequency of CDI
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recurrence.22 Wullt et al. found no significant differences between the two groups in the
cure rate of initial CDI or the recurrence of CDI.20

Objectives and Specific Aims
The main objective of this study is to describe the use of a blend of Lactobacillus
acidophilus and Lactobacillus helveticus (Lactinex®, Becton-Dickson, Co.) by CDI
patients.29 The secondary objective is to examine the relationship between the use of
Lactobacillus and various CDI related clinical outcomes.
The project has the following specific aims:
Specific Aim 1: Describe the demographic and clinical characteristics (age, gender,
and race, CDI status, number of antibiotics received, transfer status, severity of
illness, mortality, readmission, and overall length of stay) of patients who did and did
not receive Lactobacillus.
Specific Aim 2: Describe the initiation of Lactobacillus with respect to initiation of
initial antibiotic therapy among patients who were on Lactobacillus.
Specific Aim 3: Describe the initiation of Lactobacillus with respect to the initiation
of CDI treatment among patients who were on Lactobacillus and had CDI.
Specific Aim 4: Among patients who had nosocomial CDI, examine the relationship
between Lactobacillus use and:
a. Length of stay
b. Switch rate of CDI treatment (i.e., metronidazole to vancomycin or vice versa)
c. Readmission with CDI
3

d. Mortality

Significance
Based on review of published research, this study is the first descriptive study of
the use of probiotics in CDI patients using a relatively large sample size. A meta-analysis
by McFarland compared the efficacy of probiotics for the treatment of CDI based on the
published randomized clinical trials (RCTs) in adult hospitalized patients. This metaanalysis concluded that probiotic therapy is effective in the treatment for CDI. The pooled
relative risk from the six RCTs included was 0.59 (0.41, 0.85) for CDI in probiotics users.
The heterogeneity of the included studies was not significant; however, the relatively small
number of trials included could be a limiting factor in this meta-analysis.18
Several methodological issues have plagued prior research on the use of probiotics
in CDI patients including small sample sizes, inappropriate or inadequate control groups,
and lack of control for co-morbidities and other confounders.18, 20, 22, 24, 25, 30, 31
Additionally, these studies have shown contradictory results of the effect of Lactobacillus
on the treatment of CDI primarily because of insufficient power to detect significant
differences due to differences in the study population, type and dose of probiotics given, or
the duration of treatment.18, 19
This study seeks to describe the demographic and clinical characteristics of
Lactobacillus users and non-users utilizing information from the Clinical Resource
Manager (CRM) administrative database from the University HealthSystem Consortium
(UHC) [Specific Aims 1-3]. This database has a large number of hospitalized patients from
4

participating teaching hospitals around the nation. Additionally, this study examines the
relationship between the use of Lactobacillus by CDI patients and various related health
outcomes [Specific Aim 4]. The findings of this study could be used to generate
hypotheses for future studies.

5

CHAPTER 2 LITERATURE REVIEW
Antibiotic-Associated Diarrhea
Antibiotic-associated diarrhea (AAD) is defined as otherwise unexplained diarrhea
that occurs in association with the administration of antibiotics.32 Clindamycin,
cephalosporins, broad-spectrum penicillins, and fluoroquinolones are more likely to cause
the problem than other antibiotics, even though all antibiotics are implicated.53 The rates of
diarrhea associated with parenterally administered antibiotics, especially those with
enterohepatic circulation, are similar to rates associated with orally administered agents.33
The incidence of AAD in hospitalized adult patients could be (13–29%), or even up to
60% during hospital outbreaks, but is rare in an out-patient and ambulatory setting
(<0.1%).34, 35 The primary cause of AAD is the disruption of intestinal normal flora by
antibiotics, which may lead to overgrowth of pathogens and colonization of the intestine.
The most commonly diagnosed and potentially severe form of AAD is caused by C.
difficile. This pathogen is implicated in 20% to 30% of patients with AAD, in 50% to 70%
of those with antibiotic-associated colitis, and in nearly all cases of antibiotic-associated
pseudomembranous colitis.2,36 Besides C. difficile infection, other factors involved in AAD
include overgrowth of other pathogens, impaired fecal fermentation, and changes in dietary
fiber intake.37, 38

6

Pathogenesis of AAD
Figure 2.1 below shows the pathogenesis of AAD. The primary cause of AAD is
the disruption of intestinal normal flora which acts as a protective barrier that resists the
colonization of pathogens in the intestine.36

Figure 2.1. Pathogenesis of antibiotic associated diarrhea (Adapted from Ref. 36)
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In addition, the disruption of intestinal normal flora diminishes its function of
digestion of non-absorbable carbohydrates, normally metabolized by colonic bacteria as an
energy source. The production of lactic acid and short-chain fatty acids by the anaerobic
flora is decreased, which increases the osmotic pressure in the colon. That reduces
absorption of water and electrolytes in the colon and results in osmotic diarrhea.39
Other factors potentially implicated in the pathogenesis of AAD are related to some
antibiotic, such as penicillins, allergic and toxic effects on intestinal mucosa and to some
antibiotic, such as macrolides, pharmacologic effects on intestinal motility. C. difficile is
another important etiology of AAD.28

Clostridium Difficile Infection
Clostridium difficile infection (CDI) is most commonly associated with the
exposure to antibiotics, especially cephalosporins, broad spectrum penicillins,
clindamycin, and fluoroquinolones.53 A small but increasing percentage of cases may also
experience megacolon, perforation, colectomy, or death. Patients with CDI may have an
increase in the length of stay by 8 to 36 days, a 20% to 65% increase in the rate of
subsequent infections, as well as a two- to three-fold increase in mortality.6-8, 42 In addition,
CDI incurs substantially greater costs. 1, 2, 10, 11

8

Epidemiology of CDI
C. difficile is the most common identified cause of nosocomial diarrhea. In a recent
study, C. difficile was determined to be the causative agent of diarrhea in 19 out of 44
(43%) patients with nosocomial diarrhea.40, 41 This pathogen is implicated in about 10% of
cases of nosocomial diarrhea, 20% to 30% of patients with AAD, in 50% to 70% of those
with antibiotic-associated colitis, and in nearly all cases of antibiotic-associated
pseudomembranous colitis.1, 2, 36 In 1995, Barbut et al. found that the prevalence of CDI in
patients who were suspected of having nosocomial diarrhea was 35 out of 344 (10.2%).42
In a similar retrospective study by Rohner et al. in 1998, the prevalence rate was 248 out of
2,531 (9.8%).43 The clinical presentations of CDI include lower abdominal discomfort,
diarrhea, colitis, and in severe cases can result in pseudomembranous colitis, toxic
megacolon, or death.44 About 3.2% of patients with CDI have complications requiring
colectomy, while in 1%-2% of patients it results in death.45, 46 However, this figures
dramatically increases in severe cases. In 2001, Barbut found that among patients requiring
a colectomy for toxic megacolon or perforation, the mortality rate was 35%-50%.42
In hospitals and long-term facilities, CDI is more common, with estimates of 25-60
cases per 100,000 occupied bed-days, compared to 7.7 cases per 100,000 person-years in
the community.47 A surveillance study in 2009 found similar results in Canadian hospitals
with an overall incidence rate of nosocomial CDI for hospitalized adult patients of 4.6
cases per 1,000 patient admissions or 65 per 100,000 patient-days.5 Among hospitalized
children, a study by Kim et al. in the United Sates found that the annual incidence of CDI
was 6.5 cases per 10,000 patient-days and 4.0 cases per 1,000 admissions.48
9

During the current decade, there has been a dramatic increase in the incidence and
severity of CDI in healthcare settings. Based on the International Classification of
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code for CDI (008.45), to
measure CDI prevalence, McDonald et al. found that the proportion of hospital discharges
with CDI code increased from 0.37% in 2000 to 0.51% in 2003 for an estimated 178,000
CDI cases in patients discharged from short stay hospitals in 2003.49 These clinically
relevant changes are temporally associated with the emergence of a hypervirulent strain of
C. difficile that has now become widely disseminated.50

CDI Impact on the Healthcare System
A recent study by Marya et al. found that there was a 23% annual increase in CDI
hospitalizations in the 6-year period from 2000 through 2005. Also, the absolute number of
CDI hospitalizations more than doubled in almost all age groups as shown in Table 2.1 or
Figure 2.2.51
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Table 2.1 – Absolute numbers of adult hospitalizations with Clostridium difficile, by
age group, United States, 2000–2005
Hospitalizations
18–44 y
45–64 y
65–84 y
>85 y
All adult
(Source: Ref. 51)

2000
14,738
28,280
69,018
22,325
134,361

2001
15,001
29,527
74,010
25,194
143,732

2002
18,747
39,421
98,148
31,899
188,215

2003
19,393
43,290
105,404
35,363
203,450

2004
22,168
50,898
122,875
43,341
239,282

2005
25,662
61,757
147,675
56,209
291,303

Figure 2.2 – Changes in the age-specific Clostridium difficile–associated disease
incidence rate per 10,000 population in the United States, 2000–2005. (Source:
Ref. 51)
11

The length of hospital stay for patients with CDI was found to increase by 8 days
among adult inpatients and 36 days in geriatric patients.42 McFarland et al. found that costs
are particularly high for patients with recurrent CDI due to the long duration of the disease,
the costs involved in diagnosis, treatment, hospitalizations, and recurrent treatments.2 They
also found that while the average cost of the first episode was $1,914, the average cost for
subsequent episodes was $3,103 totaling on average to $10,970 for patients with multiple
episodes. Kyne et al. performed an analysis of CDI-attributable costs using a cohort study
design and found it to be $3,669 (95% confidence interval [CI] $1,126 to $7,024) per
episode. Another recent study using a retrospective cohort study design found that CDI
was associated with excess costs of $3,240 (P < 0.001; increase in cost, 33%) and with
$5,042 (95% CI $3,797 to $6,481; increase in cost, 53%) attributable inpatient costs over
180 days.11

Risk Factors for CDI
Major risk factors for CDI include antibiotic exposure, hospitalization or admission
to a long-term care facility, and advanced age.52, 53 Other risk factors of recurrent CDI are
increasing age, increased severity of underlying disease, and low serum antibody response
to toxin A.45,53 The use of gastric acid-inhibitors, especially proton pump inhibitors (PPI),
has also been proposed as a possible risk factor.54 In a recent case-control study by Aseeri
et al. in 2008, PPI use was associated with an increased risk of CDI (OR = 3.6, 95% CI 1.7
to 8.3; P < 0.001).55
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C. difficile spores can be transmitted through the fecal-oral route in the public;
however, the spores are more prevalent in hospital and long-term care facilities.
Transmission can occur through infected patients, contaminated surfaces in hospitals, or
through personnel whose hands are contaminated by the bacteria.45 In general, exposure to
the healthcare setting also increases the risk of developing CDI. Within the hospital setting,
patients admitted to an intensive care unit and those having a prolonged hospital stay are
more likely to become infected with C. difficile.53
Exposure to almost any antibiotic can predispose a patient to a C. difficile infection.
Historically, it is known that clindamycin, cephalosporins, and certain broad spectrum
penicillins were most commonly associated with CDI.53 Although most of the published
literature identifies antibiotic use and hospitalization as the primary risk factors for CDI,
there is some evidence to the contrary. A recent review article by Thomas et al. identifies
several biases in articles reporting a relation between antibiotic use and CDI;56 while a
study by Wilcox found that only 50% of C. difficile cases had taken antibiotics in the
previous month and only 32% had been hospitalized in the previous 6 months.
Advanced age also has been found to be a significant risk factor for the CDI.
Patients older than 65 years have more than 15-fold greater chance of developing CDI
compared with younger patients.12, 57 Immunosuppressant and chemotherapy have also
described as risk factors for CDI; however, this hypothesis has been questioned by
others.53
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Diagnosis of CDI
The diagnosis of CDI is generally based on the detection of C. difficile toxins (A,
B, or both) in the stool. Usually only symptomatic patients are tested using diarrheal stool
specimens as there is no value of testing stool samples of asymptomatic patients unless an
outbreak is being investigated.45 Culture of the stool for the C. difficile bacteria is another
sensitive test; however, not all C. difficile strains produce toxin and the test may be
positive for a non-toxicogenic strain. This test is not used routinely except in some
research studies since it may require 48 hours for a culture to become positive.59
Tissue culture assay for cytotoxicity of toxin B is considered the “gold standard”
for diagnosing CDI with a sensitivity of around 80%-100% and a specificity of 99%.
Because of the sensitivity of the test, it is not usually necessary to test multiple stool
samples.45, 47, 59
Many clinical laboratories use the enzyme-linked immunosorbent assay (ELISA)
method, which can be performed more quickly than culture assay, usually within hours.
This assay can detect either toxin A or B in stool and is very specific but less sensitive.
This essay has been reported to have false-negative rate of up to 40%; however, it has the
ability to identify cases of toxin A negative/toxin B positive. 45, 60, 61 Polymerase chain
reaction test is another method for diagnosis of CDI and has been reported to have a very
high sensitivity but poor specificity due to difficulty in distinguishing between asymptotic
carriage and symptomatic infection.47, 62
Direct endoscopic visualization of the colonic mucosa can be useful in making the
diagnosis of CDI. To avoid possible colonic perforation with this technique, it has been
14

reserved for patients with severe disease and negative laboratory results for rapid
diagnosis.47, 59

Standard Treatment of CDI
Current treatment strategies of CDI consist of discontinuing, if possible, the
offending antibiotic. This is sufficient for mild cases of the disease. For more severe cases,
CDI is normally treated with oral metronidazole (250 mg four times a day or 500 mg three
times a day for 10-14 days) or oral vancomycin (125 mg four times a day for 10-14 days).
For severe cases, oral vancomycin is recommended as the first line therapy. Finally, for
severe CDI cases with complication, vancomycin 500 mg orally or via nasogastric tube 4
times per day and/or intravenous metronidazole 500–750 mg every 8 hours is
recommended.45 In moderate cases metronidazole is the preferred initial choice because of
its low price and to reduce the use of vancomycin to avoid increased resistance of
Enterococci species.45 These treatment strategies are associated with a recurrence rate of
up to 28% in patients 3 to 28 days after the antibiotic has been discontinued.6, 12 Some
evidence shows that oral teicoplanin, which is not available in the United States, may be a
better choice than vancomycin in some cases.13 For patients not responding to antibiotics,
surgical intervention may be required when colonic perforation or toxic megacolon is
suspected.45

15

Probiotics
Probiotics, defined as live microbial dietary supplements that beneficially affect the
host by improving intestinal microbial balance,15 have been used as a way of restoring
intestinal microflora. This acts as a protective barrier that resists the colonization of
intestinal pathogens and consequently decreases the incidence and duration of AAD in
general. Probiotics may also prevent and treat CDI. They are relatively inexpensive,
generally safe, and well tolerated.16 There are different types of probiotics that have been
used for the prevention and treatment of CDI, including various strains of Lactobacillus
(Lactobacillus GG, Lactobacillus rhamnosus, Lactobacillus casei, and Lactobacillus
plantarum 299v) and the yeast Saccharomyces (Saccharomyces boulardi and
Saccharomyces cerevisiae). Lactobacillus GG and Saccharomyces boulardii were shown
to be more effective and more commonly used than other probiotics.63, 64 In addition,
probiotics have many other potential positive health effects.24, 27, 28

Mechanism of Action
As mentioned before, disturbance of the normal colonic flora prompts colonization
of C. difficile.45 Probiotics may prevent or treat the colonization by pathogens through
restoring the equilibrium in the altered gastrointestinal normal flora.65 Several potential
mechanisms of action have been suggested by which probiotics can promote
gastrointestinal health. Probiotics competitively inhibit pathogen adherence to colonic
epithelial and mucosal cells. This keeps the tight junction proteins intact and prevents both
uptake of intact macromolecules and translocation of organisms to the mesenteric lymph
16

nodes. Also, probiotics can enhance production and secretion of anti-inflammatory
cytokines, including interleukin-10. Stimulation of secretory immunoglobin A and other
immunoglobins by the immune system is another proposed mechanism of action.66 In
addition, probiotics may enzymatically modify toxin receptors and compete with
pathogens for nutrients.45, 56, 67

Pharmacokinetics of Probiotics
The beneficial effects of probiotics depend on their ability to protect the active
constituents, such as enzymes, against gastric acidity and deliver them to the colon. The
survival of probiotics in the gastrointestinal tract differs widely depending on their intrinsic
resistance, host factors, and the formulation used, Figure 2.4.68
Pharmacokinetic studies of S. boulardii and Lactobacillus acidophilus in healthy
volunteers have shown that it reaches steady state levels of 1 × 108 colony-forming units
(CFU)/gram after three days of oral dosing with 0.5gram (1 × 1010 CFU/g) twice a day.69
The amount of probiotics in the colon declines rapidly after cessation of dosing.
As part of a randomized study on S. boulardii for the treatment of recurrent CDI,
Elmer et al. measured S. boulardii concentrations at various times in the stool samples of
patients. Patients in the intervention group received 1gram of lyophilized S. boulardii per
day containing about 10 × 109 CFUs along with either vancomycin or metronidazole. Of
the 50 intervention group patients, 41 (82%) had detectable stool concentrations of S.
boulardii ranging from 1.5 × 103 to 6.2 × 107 CFUs per gram. Furthermore, they found S.
boulardii concentrations were higher in patients who did not have a recurrence of CDI (1 ×
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106 CFU per gram compared to 1.5 × 104 CFU per gram). These differences were not
explained by age, gender, or antibiotic type/dose. The same study found that S. boulardii
was cleared by 94% of patients by the third day after treatment was discontinued.69

Figure 2.3 – Classification of probiotics according to their resistance in the
gastrointestinal tract
Note: Some ingested probiotics are rapidly destroyed in the stomach (A), whereas others survive better
beyond the stomach but are destroyed by bile (B) or by the endogenous flora (C). Some probiotics have a
high survival through the gastro intestinal tract (D), close to that of a marker (M). (Source: Ref. 68)
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Probiotics for Treatment of CDI
There have been several studies reported in the last three decades looking at the
effect of probiotics, including Lactobacillus spp and Saccharomyces spp on the treatment
of CDI. 7, 8, 18-26, 63, 64 These studies may have shown contradictory results because of
insufficient power to detect significant differences due to differences in the study
population, type and dose of probiotics given, or the duration of treatment.18, 19
In a letter to the Lancet in 1987, Gorbach et al. described the successful treatment
of five patients with recurrent CDI using Lactobacillus GG. All patients (n = 5) had
multiple recurrences within a 10-day period after antibiotic therapy. Following treatment
with Lactobacillus GG there was no recurrence for periods ranging from four months to
four years.72 A study by Surawicz et al. reported cessation of CDI in 11/13 (84.6%)
patients treated with S. boulardii.23 Kimmey et al published a case report of a 67-year-old
woman using S. boulardii to treat and prevent recurrent CDI. Over 8 months the patient
experienced 8 CDI recurrences. The patient was treated with a 4 week course of
vancomycin. After failing to resolve the diarrhea, S. boulardii was added with another
vancomycin regimen until semi-formed stools developed. She took the probiotic for total
of about 90 days.73
In a case study, Pakyz reported a use of Lactobacillus in the treatment of a
recurrent CDI case in an 87-year-old resident of a long-term care facility. Two weeks after
discharge from a hospital, the patient was readmitted for altered mental status, fever, and
diarrhea. The patient was positive for C. difficile stool culture so she was placed on oral
metronidazole and Lactobacillus. After five days of therapy, patient showed no minimal
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improvement in diarrheal symptoms and was switched to oral vancomycin and
Lactobacillus. Symptoms of diarrhea disappeared after 14 days of therapy.74
Table 2.2 summarizes six RCTs that evaluated the effect of different types of
probiotics in the treatment of CDI or recurrent CDI. In a randomized, double-blind,
placebo-controlled study, McFarland et al. studied 124 patients with active diarrhea and a
positive result from at least one C. difficile assay (culture, toxin A, or toxin B) who were
treated with vancomycin and/or metronidazole.24 The intervention group (n = 57) was
randomly selected to receive a lyophilized 500mg capsule of S. boulardii twice daily and
the control group (n = 67) to placebo for 4 weeks. Approximately half (n = 60) of the
patients had at least one prior CDI. Patients were excluded if they had AIDS or if they
were immunosuppressed secondary to chemotherapy within the past three months. CDI
recurrence rates were calculated for 4 weeks after discontinuing the S. boulardii. Overall
the treatment failure rate was 26.3% in the S. boulardii group versus 44.8% in the placebo
group (P = 0.05). In the patients with history of CDI, 34.6% of the treatment group failed
therapy versus 64.7% of placebo patients (P = 0.04). Compared to the control, those in the
treatment group were significantly more likely to experience cessation of diarrhea
(Relative Risk [RR] = 1.33; 95% CI 1.02 to 1.74) and were significantly less likely to
experience recurrence of diarrhea after cessation of antibiotic therapy (RR = 0.59; 95% CI
0.35 to 0.98). Although the treatment group was small, these results suggested that patients
experiencing at least one recurrent episode of CDI may benefit from S. boulardii treatment.
The main conclusion of the authors was that there was a statistically significant beneficial
effect of S. boulardii on recurrent CDI, particularly among patients who have had at least
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one prior episode of CDI. One of the limitations of this study was not accounting for
severity of illness.50
Surawicz et al. studied 168 adult patients with recurrent CDI, defined as one or
more previous episodes of diarrhea that had a positive C. difficile assay and initial response
to antibiotic treatment.22 Patients were divided into three treatment groups: high dose oral
vancomycin (2 g/day; n = 32), oral low dose vancomycin (500 mg/day; n = 85), or oral
metronidazole (1 g/day; n = 53), all for 10 day. The oral high dose vancomycin group was
randomized to receive either S. boulardii 500 mg twice daily (n = 18) or placebo (n = 14)
for 28 days starting on day 7 of the 10 day course of antibiotic. They were followed for a
total of two months. No information about the other two groups was provided. In the high
dose oral vancomycin treatment group, a 16.7% recurrence rate versus a 50% recurrence
rate in the placebo group (P = 0.05; RR = 0.33; 95% CI 0.10 to 1.06). S. boulardii did not
significantly decrease the recurrence rate in either the vancomycin 500 mg daily group or
the metronidazole group. The authors concluded that there was a beneficial effect of S.
boulardii in patients treated with high dose vancomycin even though this is in a small
group of 32 patients. This was surprising, however, because these patients had more
serious manifestations of CDI than other sub-groups and the confidence interval was very
wide.22
In 2003, Wullt et al. in a multi-center randomized double-blind placebo controlled
study examined 21 adult patients with recurrent CDI. Patients were included if they had
ongoing diarrhea and a positive C. difficile toxin assay within six days of enrollment or if
they had CDI within the previous two months and were not being treated with a list of
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drugs including vancomycin and metronidazole at the time of enrollment. Patients were
randomized to receive oral metronidazole 400 mg three times daily for 10 days in
combination with either fruit drink containing Lactobacillus plantarum 299v once daily (n
= 12) or placebo (n = 9) for 38 days. A total of only 21 patients completed the study across
the nine centers over the two-year period. No statistically significant differences between
the two groups were seen in the cure rate of initial CDI (RR = 0.93; 95% CI 0.73 to 1.19),
recurrence of CDI (RR = 0.55; 95% CI 0.22 to 1.35), or cure rate by stool assay (RR =
0.75; 95% CI 0.41 to 1.36). The numbers of patients involved in this study were too small
to allow any strong conclusions. The authors’ concluded that probiotics either counteract
the pathogenesis of C. difficile or have a positive overall impact on the microflora that
prevents clinical recurrence; however, they did not provide any results to support that
conclusion.26
Lawrence et al. conducted a randomized double-blind placebo controlled pilot
study in a total of 15 adult patients with recurrent CDI. Patients were included if they had
ongoing diarrhea and a positive C. difficile toxin assay and history of CDI in the preceding
year. Exclusion criteria included critical or terminal illness, compromised immunity, more
than five days of CDI treatment, and recent probiotic use. Patients were randomized to
receive either 40 mg lyophilized Lactobacillus GG twice daily (n = 8) or placebo (n = 7)
for 28 days in addition to the CDI treatment and were followed for 60 days. A total of three
(37.5 %) cases of RCDI were observed in the Lactobacillus arm and one (14.3 %) in the
placebo arm (RR = 2.6; 95 % CI 0.3 to 19.9). No conclusion was provided since the study
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was not powered to detect a difference in outcomes for interest; that also resulted in a very
wide confidence interval. The study was well designed but had a very small sample size.30
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Table 2.2 – Description of reviewed studies

Study
McFarland LV
1994
Surawicz CM
2000
Pochapin M
2000
Wullt M
2003
Plummer S
2004
Lawrence SJ
2005

No. and Type
of Subjects
124 Adults with
CDI or RCDI
32 Adults with
RCDI
25 Adults with
CDI or RCDI
20 Adults with
RCDI
138 Inpatients
varied ages
15 Adults with
RCDI

Probiotic-Treated
Control Group
Group
Probiotic Treatment FollowCured (%) Failed Cured (%) Failed
Up
Probiotic Dose / Day Duration
SB + V/M

2 × 1010

4 wk

4 wk

42 (73.68)

15

37 (55.22)

30

SB + V

2 × 1010

4 wk

4 wk

15 (83.33)

3

7 (50.00)

7

N/R

3 wk

0

7 (63.63)

4

9 (64.28)

5

5 × 1010

38 days

0

7 (63.63)

4

3 (33.33)

6

2 × 1010

20 days

0

67 (97.10)

2

63 (91.30)

6

6 × 1011

3 wk

4 wk

5 (62.50)

3

6 (85.71)

1

LGG + V
or M
LP 299v +
M
LABB, no
V or M
LGG + V
or M

CDI: Clostridium difficile infection; RCDI: Recurrent Clostridium difficile infection; SB: Saccharomyces boulardii; LGG: Lactobacillus rhamnosus GG;
LP: Lactobacillus plantarum 299v; V: Vancomycin; M: Metronidazole, LABB =Lactobacillus acidophilus and Bifidobacterium bifidum;N/R: Not
reported. (Source: Reference 18)
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A meta-analysis by McFarland compared the efficacy of probiotics for the
treatment of CDI based on the published RCTs (n = 6) in adult hospitalized patients, Table
2.2. This meta-analysis concluded that probiotic therapy is effective in the treatment of
CDI. The pooled relative risk (Figure 2.4) for CDI associated with probiotic use from the
six RCTs included was 0.59 (95% CI 0.41 to 0.85). The heterogeneity of the included
studies was not significant; however, the relatively small number of trials included could
be a limiting factor in this meta-analysis.18
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Figure 2.4 – Forest Plot of six randomized controlled trials of probiotics for the
treatment of Clostridium difficile Infection. (Source: Ref. 18)
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CHAPTER 3 METHODOLOGY
Data Source
The data used in this study were obtained from the Clinical Resource Manager
(CRM) program developed and maintained by the University HealthSystem Consortium
(UHC; www.uhc.edu). UHC is an alliance of 102 academic medical centers representing
approximately 90% of the nation’s non-profit academic medical centers. UHC provides
programs and services to improve clinical, operational, and patient safety performance.75
The CRM database program brings together data from a subset of participating hospitals,
with the actual number of hospitals in the database varying by the year. The information in
the database is obtained from various sources including patient encounters, billing
information, transactional data, as well as discharge summaries to provide standardized
information on in-hospital resource utilization and patient outcomes.76 The drug use data in
the CRM has been previously validated.77

Study Design
The study was composed of two general parts: descriptive and analytical. First, the
demographic and clinical characteristics of Lactobacillus users and non-users were
described (Specific Aim 1) using cross sectional study design. Among probiotic users, the
initiation date of probiotics was described with respect to the initial antibiotic therapy
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initiation date (Specific Aim 2) and CDI treatment initiation date (Specific Aim 3). The
second part of this study is a retrospective cohort study (Specific Aim 4). A cohort of all
nosocomial CDI patients in the CRM database was reviewed for certain CDI-related
outcomes of interest. The relationship between the use of Lactobacillus and switch rate of
CDI treatment, readmission for CDI, mortality, and post-CDI-diagnosis length of stay were
examined. This study was approved by the Institutional Review Board at Virginia
Commonwealth University.

Study Sample
The data for this project were derived from a separate study designed to examine
the risk of CDI associated with various antibiotic agents.9 It examined all patients having
an ICD-9-CM code for CDI (008.45) and two controls for each case. Controls were
randomly drawn from the same hospital and quarter of discharge as the cases.
Lactobacillus may be considered a non-formulary agent at some institutions. This can
result in unreported usage of the agent. Only those hospitals reporting Lactobacillus usage
were included in this study. For the current study, data were obtained from hospitals
participating in the CRM during the period from July 1, 2003, to December 31, 2005,
representing 2.5 years in the study period. The analysis was limited to that period because
it has relatively high number hospitals who consistently report Lactobacillus use and large
number of CDI patients. The data included the following information for each patient:
demographic characteristics, detailed antibiotics use (e.g., name, start date, end date, and
length of therapy ), admission and discharge dates, total length of stay, the All Patients
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Refined-Diagnosis Related Group (APR-DRG) severity of illness category,78 and all
discharge diagnosis codes. All data were obtained directly from UHC.
Patients included in the analysis were 18 years of age or older and discharged from
one of the participating hospitals during the study period. Based on unique patient
identification numbers and admission dates, cases of recurrent CDI (readmission) were
able to be identified.

Analysis Variables
For the first part of the study, users and non-users of Lactobacillus were described
with respect to various patient demographic characteristics, CDI status (i.e., no CDI,
nosocomial CDI, and non-nosocomial CDI). Lactobacillus users were also described with
respect to when Lactobacillus was started in relation to antibiotic therapy and CDI
treatment. Post-CDI-diagnosis length of stay, switch rate of CDI treatment (i.e., switching
from vancomycin to metronidazole or vice versa), readmission for CDI, and mortality, are
the outcome variables for the second phase.
The primary independent variable of interest for the models in the second part of
the study was the use of Lactobacillus. Many potential confounding variables were
included in the analysis. These included sex, race, transfer from outside hospital status,
switch of CDI treatment status, severity of illness, comorbidity, and mortality.
Comorbidity was measured using the Dartmouth-Manitoba version of the Charlson
Comorbidity Index (DM-CCI), which is an adaptation of the original Charlson
Comorbidity Index (CCI) to utilize the ICD-9-CM codes from administrative data.58, 79 The
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CCI is a list of 19 medical conditions which were selected and weighted based on the
strength of their association with mortality. The comorbidity score is the total sum of
weights assigned to each condition. The DM-CCI was selected as a measure of
comorbidity because it is based on an ICD-9-CM coding system, which is the same coding
system used in our database. DM-CCI has been validated in a study, by Ghali et al.
comparing it two other comorbidity indexes.17

Methods
As mentioned previously, this study has two general parts: a descriptive part
(Specific Aims 1-3) and an analytical part (Specific Aim 4). Throughout the study CDI
cases are described as nosocomial or non-nosocomial. The nosocomial cases must meet
two criteria, the ICD-9-CM code for CDI and starting CDI treatment (metronidazole or
vancomycin) on or after day five of hospitalization. Those CDI cases starting treatment
before day five were considered non-nosocomial cases.77 Based on prior research,
switching of CDI treatment, readmission for CDI, mortality, and length of stay were
selected as the outcomes of interest. These variables are not only represent the morbidity
and mortality of patients but also measure the impact of CDI to healthcare system. The
exposure variable of interest is the use of a blend of Lactobacillus acidophilus and
Lactobacillus helveticus (Lactinex®).
For the first aim, all patients receiving Lactobacillus were compared to those not
receiving Lactobacillus. The demographic characteristics (age, gender, and race) and the
clinical characteristics (CDI status, number of antibiotics received, transfer status, severity
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of illness, mortality, readmission, and overall length of stay) were described. Analytical
weights were used in this descriptive piece to take into account the way in which the
controls were sampled. These weights are described in the next section. The top 5 ICD-9CM discharge diagnosis codes for Lactobacillus users and non-users in the total sample,
CDI cases (both nosocomial and non-nosocomial), and non-CDI cases were identified. The
number and percentage of patients who had the code and the description of the code were
reported. Also, the distribution of antibiotics used by study patients was described.
Antibiotics were classified into seventeen different classes or individual drugs: penicillins,
penicillinase-resistant penicillins, broad spectrum penicillins, 1st generation
cephalosporins, 2nd generation cephalosporins, 3rd and 4th generation cephalosporins,
carbapenems, aminoglycosides, fluoroquinolones, macrolides, tetracyclines,
trimethoprim/sulfamethoxazole, other sulfonamides, clindamycin, vancomycin,
metronidazole, and miscellaneous antibiotics. The specific agents in each class are
provided in Table 3.1. For each class of antibiotics the frequency and percentage were
reported.
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Table 3.1 – Antibiotic agent classifications
Antibiotic class
Penicillins

Antibiotic agents
Penicillin G, penicillin V, amoxicillin, amoxicillin/clavulanate
potassium, ampicillin, ampicillin/sulbactam

Penicillinaseresistant penicillins
Extended-spectrum
penicillins

Cloxacillin, dicloxacillin, methicillin, nafcillin, oxacillin

1st generation
cephalosporins

Cefadroxil, cefazolin, cephalexin, cephalothin, cephapirin,
cephradine

2nd generation
cephalosporins

Cefaclor, cefprozil, cefonicid, cefotetan,cefoxitin, cefuroxime,
loracarbef, cefditoren, cefamanadole

3rd and 4th
generation
cephalosporins

Cefixime, cefoperazone, cefotaxime, ceftazidime, ceftizoxime,
cefpodoxime, ceftriaxone, cefmetazole, cefdinir, ceftibuten,
cefepime

Carbapenems

Imipenem/cilastatin, ertapenem, meropenem

Aminoglycosides

Amikacin, gentamicin, kanamycin, netilmicin, streptomycin
sulfate, tobramycin, neomycin

Fluoroquinolones

Lomefloxacin, norfloxacin , ofloxacin, moxifloxacin, gatifloxacin,
ciprofloxacin, levofloxacin, sparfloxacin, trovafloxacin

Macrolides

Azithromycin dehydrate, clarithromycin, erythromycin,
troleandomycin, dirithromycin

Sulfonamide
combinations
Other sulfonamides

Sulfamethoxazole/trimethoprim

Tetracyclines

Demeclocycline, doxycycline hyclate, minocycline,
oxytetracycline, tetracycline

Carbenicillin disodium, carbenicillin indanyl sodium, mezlocillin,
piperacillin, ticarcillin, ticarcillin/clavulanate,
piperacillin/tazobactam

Sulfadiazine, sulfamethoxazole, sulfasalazine, sulfisoxazole

(cont.)
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Table 3.1 (continued)
Lincosamides

Clindamycin

Glycopeptides

Vancomycin

Imidazoles

Metronidazole

Miscellaneous
antibiotics

Aztreonam, colistimethate, methenamine hippurate, methenamine
mandelate, metronidazole, moxalactam, polymyxin b sulfate,
spectinomycin, trimethoprim, vancomycin, bacitracin, linezolid,
daptomycin, fosfomycin, trimetrexate glucuronate,
quinupristin/dalfopristin, chloramphenicol, tigecycline,
telithromycin, furazolidone, nitrofurantoin, nitrofurantoin,
macrocrystals, rifaximin
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For the second aim, the day on which Lactobacillus was initiated with respect to
antibiotic therapy initiation dates were described among patients who were on antibiotics
and Lactobacillus. The frequency and percentage of patients who started Lactobacillus at
each initiation day were reported. The percentages were also reported by CDI status.
For the third aim, the day Lactobacillus was initiated with respect to CDI
treatment initiation dates were described among CDI patients who were using
Lactobacillus. The frequency and percentage of patients who started Lactobacillus at each
initiation day were reported. The percentages were also reported by CDI status.
For the fourth aim, the sample included all nosocomial CDI patients and the
exposure variable of interest is Lactobacillus use. The crude (un-adjusted) relationship
between Lactobacillus use and the following CDI related outcomes were calculated: switch
rate of CDI treatment, readmission for CDI, mortality, and post-CDI-diagnosis length of
stay. The adjusted relationships between Lactobacillus use and the same outcomes of
interest were examined and reported while adjusting for various potential confounders,
such as age, sex, race, transfer from outside hospital status, switch of CDI treatment status,
severity of illness, intensive care unit (ICU) days, Charlson score, and mortality.
Comorbidity and other potential confounding variables were accounted for in the analysis
for more accurate assessment of the relationship. For assessment of crude and adjusted
relationship between Lactobacillus use and switch rate of CDI treatment only those who
used Lactobacillus before diagnosis were considered in the analysis
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Statistical Analysis
Descriptive statistics including the mean and standard deviation or median and 25th
and 75th percentiles for continuous variable or proportion with 95% confidence intervals
for categorical variables were calculated for all demographic and clinical characteristics
measured. For the comparison of continuous variables that were approximately normally
distributed, the Student’s t-test was used. For non-normally distributed variables, the
Wilcoxon rank sum test was used. Fisher’s exact test was used for categorical data. The
relationship between Lactobacillus use and each of categorical outcome variables (switch
rate of CDI treatment, readmission for CDI, and mortality) were examined with a multiple
logistic regression model. A linear regression model was built for the examination of the
relationship between Lactobacillus use and length of stay. Odds ratios from the logistic
regression model and their 95% confidence intervals were reported for all categorical
variables. From the linear regression model, the regression coefficients and 95%
confidence intervals were reported. All potential confounders were accounted for in the
data analysis to assure a more accurate assessment of the relationship between
Lactobacillus and the selected outcome variables. For all analyses, statistical significance
was determined using two sided Type I error level of 5%. Statistical analyses were
conducted using Stata/SE version 10.0 (Stata Corporation, College Station, TX).
In the original dataset, all patients with an ICD-9-CM code for CDI were obtained
from the CRM database within the study period. The non-CDI patients were sampled so
that there were two of these non-CDI drawn from the same quarter and hospital as each
CDI patient. To account for this random sampling approach, a set of analytical weights
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were derived. These weights are equal to the inverse of the probability of being sampled.
Since all patients with a CDI diagnosis code were sampled, their weight was equal to 1.
For the controls, the weights were equal to the inverse of twice number of cases identified
for a given hospital and quarter divided by the total number of discharges for that quarter
less twice the number of cases. This weight can be represented as shown in the following
equation where wi is the weight for patient i, cj is the number of cases from hospital j, and
dj is the number of adult discharges for hospital j.
 2c j
wi = 
 d − 2c
j
 j





−1

These weights were applied when performing the descriptive analysis for Specific Aim 1.
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CHAPTER 4: RESULTS
Hospital Characteristics
A description of the general characteristics of participating hospitals in the study
sample are presented in Tables 4.1 and 4.2. The data used in this study represent 31
teaching hospitals from six different regions throughout the nation. About half of the
hospitals were from the Midwestern or Southeastern region (22.58% each). The other half
were mainly from Mid-Atlantic or Mid-Continent regions (19.35% each). Only two
hospitals were from New England region, 6.45%. The capacity of these hospitals range
from 156 to 805 beds (mean = 513.97, SD = 153.57). About 70% of the hospitals have a
capacity range from 300 to 600 beds. All of the participating hospitals had a case mix
index (CMI) over one ranging from 1.46 to 2.13, (mean = 1.81, SD = 0.16). That means
these hospitals treat sicker patients and therefore, their adjusted cost per patient or per day
is more than the average reimbursement by Medicaid.14
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Table 4.1 – Hospital characteristics
No.
Hospitals (%)

Hospital Characteristic
Region
Midwestern
Southeastern
Mid-Atlantic
Mid-Continent
Western
New England
Bed size category
1 to 199
200 to 299
300 to 499
500 to 599
600 to 699
More than 700
Bed size
Mean (SD)
Median (25th, 75th percentile)
Case mix index
Mean (SD)
Median (25th, 75th percentile)
SD: standard deviation

7 (22.58%)
7 (22.58%)
6 (19.35%)
6 (19.35%)
3 (9.68%)
2 (6.45%)
1 (3.23%)
0 (0.00%)
12 (38.71%)
10 (32.26%)
4 (12.90%)
4 (12.90%)
513.97 (153.57)
533 (396, 614)
1.81 (0.16)
1.83 (1.68, 1.92)

Study Population
The total population of this study, as shown in figure 4.1, was 35,670 patients. The
cases were 8,968 (25%) and the remaining 26,703 (75%) were controls who had no CDI.
Almost half of the cases were non-nosocomial cases 4,428 (12%) and the other half were
nosocomial cases 4,540 (13%). There were 480 Lactobacillus users majority of them had
CDI (237 (49%) had non-nosocomial CDI and 202 (42%) had nosocomial CDI). After
applying the weight there were 2,564 Lactobacillus users majority had no CDI (Figure
4.2).
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Figure 4.1 – CDI status in overall study sample
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Figure 4.2 – CDI status within Lactobacillus users [weighted percentages]
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Patients Demographic and Clinical Characteristics
Of the 480 Lactobacillus users, 439 had CDI (237 (54%) had non-nosocomial CDI
and 202 (46%) had nosocomial CDI). The average duration of use was not significantly
different among non-nosocomial and nosocomial cases, 9.55 days (SD = 16.66) and 11.29
days (SD = 18.10), respectively (Table 4.2).
The unweighted and weighted detailed description of the demographic and clinical
characteristics of Lactobacillus users and non-users are listed below (Table 4.3 and Table
4.4, respectively). Users of Lactobacillus were significantly older that non-users with
average ages of about 61.1 years (SD = 18.5) and 53.8 years (SD = 18.98), respectively.
Both groups were almost equally distributed between male and female. The majority of
both groups were Caucasian or African American. Among Lactobacillus users, 375
(78.13%) were Caucasian and 54 (11.25%) were African American. In the non-users,
21,806 (61.97%) were Caucasian and 7,597 (21.59%) were African American. There were
no big differences in race distribution after applying the weight. Also, almost all
Lactobacillus users 439 (91.46%).had CDI with 237 (49.38%) users having nonnosocomial CDI and 202 (42.08%) having nosocomial CDI. Of the non-users there were
4,191 (11.91%) non-nosocomial CDI cases and 4,338 (12.33%) nosocomial CDI cases
(Table 4.3 and Figures 4.3). Patents with no CDI [2,125 (82.88%)] were the majority after
applying the weights (Table 4.4 and Figure 4.4). With respect to the number of antibiotics
received, over 60% of the Lactobacillus users had four or more antibiotics. In the nonusers, almost 28% received no antibiotics and almost 25% received only one antibiotic
(Table 4.3 and Figure 4.5). After applying the analytical weights, the percentage of
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Lactobacillus users who did not use any antibiotics increased from 0.42% to 7.53%, and
those who used four or more antibiotics decreased from 61.88% to 55.38%. For non-users
the percentage of those who did not use any antibiotics increased from 27.68% to 36.38%
and those who used four or more antibiotics decreased from 19.47% to 8.15% (Table 4.4
and Figure 4.6). A majority of the users had an APR-DRG severity of illness category of
major (35.83%) or extreme (53.33%). Oppositely, the non-users were mainly minor
(24.97%) or major (33.25%) severity of illness category (Table 4.3 and Figure 4.7). After
applying the analytical weights, the percentage of users who were moderately ill increased
from 10.42% to 22.12% and those who were extremely ill decreased from 53.33% to
45.16%. For non-users the percentage those who were moderately ill increased from
24.97% to 32.37% and those who were extremely ill decreased from 15.72% to 6.37%
(Table 4.4 and Figure 4.8). Unlike the non-users, almost one third of Lactobacillus users
were readmitted for CDI. The average length of stay was significantly higher for users
(mean = 27.64, SD = 39.07; median = 17) than non-users (mean = 8.63, SD = 13.71;
median = 4) (P <0.001). After applying the analytical weights, the mean length of stay for
both users and non-users decreased from 27.64 days to 24.53 days and from 8.63 days to
5.44 days; respectively. Generally, there were minor differences between weighted and
um-weighted statistics.
There was small missing data (2.85%) in the race variable which was added to the
“other” category. Also, there was negligible missing data (< 0.01%) in the gender variable.
Other variables have no missing data. Three observations were dropped because their
diagnosis dates were after their discharge dates.
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Table 4.2 – Description of Lactobacillus usage by CDI patients
Lactobacillus Usage
Count (%)
Mean (SD)
Median (25th, 75th percentile)

Non-nosocomial CDI
237 (53.99)
9.55 (16.66)
6 (2, 11)

SD: Standard deviation; CDI: Clostridium difficile infection.
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Nosocomial CDI
202 (46.01)
11.29 (18.10)
6 (3, 12)

P-value
0.2965
0.2276

Table 4.3 – Patient demographic and clinical characteristic of Lactobacillus users and
non-users [Unweighted statistics]

Variables
Age in years [Mean (SD)]
Genderc [No. (%)]
Male
Female
Race [No. (%)]
Caucasian
African American
Hispanic
American Indian/Eskimo
Asian
Other
Unknown
CDI status [No. (%)]
No CDI
Non-nosocomial CDI
Nosocomial CDI
Number of antibiotics
received [No. (%)]
None
One
Two
Three
Four or more
Transferred from an outside
hospital [No. (%)]
No
Yes
Severity of Illnessd [No. (%)]
Minor
Moderate
Major
Extreme

Lactobacillus
Users (n = 480) Non-usersb (n = 35,190)
61.09 (18.15)
53.78 (18.98)
a

248 (51.67%)
232 (48.33%)

P-value
< 0.001
0.166

19,294 (54.83%)
15,892 (45.16%)
< 0.001

375 (78.13%)
54 (11.25%)
23 (4.79%)
1 (0.21%)
3 (0.63%)
12 (2.50%)
12 (2.50%)

21,806 (61.97%)
7,597 (21.59%)
2,415 (6.86%)
170 (0.48%)
550 (1.56%)
1,646 (4.68%)
1,006 (2.86%)
< 0.001

41 (8.54%)
237 (49.38%)
202 (42.08%)

26,661 (75.76%)
4,191 (11.91%)
4,338 (12.33%)
< 0.001

2 (0.42%)
35 (7.29%)
60 (12.50%)
86 (17.92%)
297 (61.88%)

9,741 (27.68%)
8,679 (24.66%)
5,929 (16.85%)
3,988 (11.33%)
6,853 (19.47%)
< 0.001

458 (95.42%)
22 (4.58%)

34,984 (99.41%)
206 (0.59%)

2 (0.42%)
50 (10.42%)
172 (35.83%)
256 (53.33%)

8,788 (24.97%)
11,701 (33.25%)
9,162 (26.04%)
5,533 (15.72%)

< 0.001

(cont.)
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Table 4.4 (continued)
Mortality [No. (%)]
No
Yes
Readmission [No. (%)]
No
Yes
Length of staye
Mean (SD)
Median (25th, 75th
percentile)

< 0.001
438 (91.25%)
42 (8.75%)

33,826 (96.12%)
1,364 (3.88%)
< 0.001

345 (71.88%)
135 (28.13%)

31,890 (90.62%)
3,300 (9.38%)

27.64 (39.07)
17 (9, 32)

8.63 (13.71)
4 (2, 9)

<0.001
<0.001

SD: Standard deviation; CDI: Clostridium difficile infection.
a
All probiotics users; bAll probiotics non-users; cThere are four non-users with unknown gender; dThere were
six non-users with no severity of illness specified; eOverall length of stay.
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Table 4.4 – Patient demographic and clinical characteristic of Lactobacillus users and
non-users [Weighted statistics]

Variables
Age-year [Mean (SD)]
Gender c [No. (%)]
Male
Female
Race [No. (%)]
White
African American
Hispanic
American Indian/Eskimo
Asian
Other
Unknown
CDI status [No. (%)]
No CDI
Nosocomial CDI
Non-nosocomial CDI
Number of antibiotics
received [No. (%)]
None
One
Two
Three
Four or more
Transferred from an outside
hospital [No. (%)]
No
Yes
Severity of Illness [No. (%)]
Minor
Moderate
Major
Extreme

Lactobacillus
Users (n = 2,500) Non-usersb (n = 1,386,538) P-value
58.92 (18.85)
51.88 (18.99)
< 0.001
0.2130
1404 (54.74%)
600,000 (43.21%)
1161 (45.26%)
790,000 (56.79%)
0.0011
2188 (85.30%)
850,000 (61.67%)
235.9 (9.20%)
290,000 (20.87%)
70.84 (2.76%)
110,000 (7.82%)
1 (0.04%)
8,332 (0.60%)
3 (0.12%)
22,000 (1.61%)
53.74 (2.10%)
65,000 (4.70%)
12 (0.47%)
38,000 (2.73%)
< 0.001
2125 (82.88%)
1,400,000 (99.38%)
237 (9.24%)
4191 (0.30%)
202 (7.88%)
4338 (0.31%)
< 0.001
a

193 (7.53%)
157.5 (6.14%)
456.2 (17.79%)
337.4 (13.16%)
1420 (55.38%)

500,000 (36.38%)
410,000 (29.30%)
240,000 (17.04%)
130,000 (9.13%)
110,000 (8.15%)
< 0.001

2542 (99.14%)
22 (0.86%)

1,400,000 (99.98%)
206 (0.02%)

2 (< 0.0018%)
567.3 (22.12%)
836.9 (32.64%)
1158 (45.16%)

450,000 (32.37%)
550,000 (39.71%)
300,000 (21.53%)
88,000 (6.37%)

< 0.001

(cont.)
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Table 4.4 (continued)
Mortality [No. (%)]
No
Yes
Readmission [No. (%)]
No
Yes
Length of stay d
Mean (SD)
Median (25th, 75th
percentile)

< 0.001
2219 (86.52%)
345.6 (13.48%)

1,400,000 (97.70%)
32,000 (2.30%)
< 0.001

2161(84.29%)
403 (15.71%)

1,300,000 (95.79%)
58,000 (4.21%)

24.53 (27.53)
19 (7, 31)

5.44 (7.733)
3 (2, 6)

< 0.001
<0.001

SD: Standard deviation; CDI: Clostridium difficile infection.
a
All estimated probiotics users; bAll estimated probiotics non-users; cThere are four missing observations
with missing/unknown gender; dOverall length of stay.
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Figure 4.3 – Unweighted CDI status of Lactobacillus users and non-users
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Figure 4.4 – Weighted CDI status of Lactobacillus users and non-users
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Figure 4.5 – Unweighted number of antibiotics received by Lactobacillus users and
non-users
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Figure 4.6 – Weighted number of antibiotics received by Lactobacillus users and nonusers
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Figure 4.7 – Unweighted severity of illness of Lactobacillus users and non-users
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Figure 4.8 – Weighted severity of illness of Lactobacillus users and non-users
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Top 5 Diagnoses Codes
In the total sample, CDI and unspecified essential hypertension were the first and
second most frequent diagnosis codes among Lactobacillus users: 443 (7.0%) and149
(2.4% ), respectively. The same codes, but in an alternate order, were the highest among
non-users; 11,838 (3.7%) and 8,622 (2.8%). Other top 5 diagnosis codes for users and nonusers in the overall sample were listed in Table 4.5.
In the CDI cases, CDI and unspecified essential hypertension, similar to the overall
sample, were the first and second most frequent diagnosis codes among Lactobacillus
users; 439 (7.5%) and 138 (2.8% ) respectively. Exactly the same diagnosis codes were
also the highest among non-users: 11,838 (3.7%) and 8,622 (2.8%), respectively. Other top
5 diagnosis codes for users and non-users among all CDI cases were listed in Table 4.6.
CDI was the number one diagnosis in this group because the diagnosis code for CDI was
used to identify CDI cases in participating hospitals for the original study.
In the non-CDI patients, volume depletion was the most frequent diagnosis code
among Lactobacillus users (12 [2.4%]). Among Lactobacillus non-users in the non-CDI
patient, essential hypertension with no complications was the most frequent diagnosis code
(8,953 [4.6%]). Other top 5 diagnosis codes for users and non-users in the overall sample
are listed in Table 4.7.
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Table 4.5 – Top 5 diagnoses ICD-9-CM codes for Lactobacillus users and non-users in
the total sample
Non-users codes

Users codes
Diagnosis (code)
Intestinal infection with
Clostridium difficile (008.45)

No.
(%)
443
(7.00)

Diagnosis (code)
Essential hypertension, unspecified
(401.9)

No.
(%)
11,838
(3.86)

Essential hypertension,
unspecified (401.9)

149
(2.35)

Intestinal infection with Clostridium
difficile (008.45)

8,622
(2.81)

Urinary tract infection, site not
specified (599.0)

144
(2.27)

Diabetes mellitus (unspecified type)
without complications not stated as
uncontrolled (250.00)

4,595
(1.50)

Volume depletion (276.5)

118
(1.86)

Coronary atherosclerosis of a native
coronary artery (414.01)

4,143
(1.35)

Congestive heart failure,
unspecified (428.0)

99
(1.56)

Esophageal reflux (530.81)

3,916
(1.28)

CDI: Clostridium difficile infection; N: Number of patients who have the code;Users: Lactobacillus users;
Non-users: Lactobacillus non-users; ICD-9-CM: The International classification of diseases, 9th revision,
clinical modification;
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Table 4.6 – Top 5 diagnoses ICD-9-CM codes for Lactobacillus users and non-users
among CDI patients
Non-users codes
Users codes
No.
No.
Diagnosis (code)
(%)
Diagnosis (code)
(%)
Intestinal infection with
439
Intestinal infection with Clostridium 8,552
Clostridium difficile (008.45)
(7.53) difficile (008.45)
(7.80)
Essential hypertension,
unspecified (401.9)

138
(2.37)

Essential hypertension, unspecified
(401.9)

2,885
(2.63)

Urinary tract infection, site not
specified (599.0)

134
(2.30)

Urinary tract infection, site not
specified (599.0)

1,936
(1.76)

Volume depletion (276.5)

106
(1.82)

Volume depletion (276.5)

1,683
(1.53)

Congestive heart failure,
unspecified (428.0)

91
(1.56)

Congestive heart failure, unspecified 1,517
(428.0)
(1.38)

CDI: Clostridium difficile infection; N: Number of patients who have the code; Users: Lactobacillus users;
Non-users: Lactobacillus non-users; ICD-9-CM: The International classification of diseases, 9th revision,
clinical modification.
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Table 4.7 – Top 5 diagnoses ICD-9-CM codes for Lactobacillus users and non-users
among non-CDI patients
Users
Non-users
No.
No.
Diagnosis (code)
(%)
Diagnosis (code)
(%)
Volume depletion (276.5)
12
Essential hypertension with no
8,953
(2.40) complications (401.9)
(4.55)
Essential hypertension with no
complications (401.9)

11
(2.20)

Diabetes mellitus (unspecified type)
without complications not stated as
uncontrolled (250.00)

3,352
(1.70)

Urinary tract infection, site not
specified (599.0)

10
(2.00)

Coronary atherosclerosis of a native
coronary artery (414.01)

3,128
(1.6)

Acute renal failure, unspecified
(584.9)

9
(1.80)

Tobacco use disorder (305.1)

3,125
(1.59)

Congestive heart failure,
unspecified (428.0)

8
(1.60)

Esophageal reflux (530.81)

3,039
(1.59)

CDI: Clostridium difficile infection; N: Number of patients who have the code; Users: Lactobacillus users;
Non-users: Lactobacillus non-users; ICD-9-CM: The International classification of diseases, 9th revision,
clinical modification.
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Distribution of Antibiotic Use in Lactobacillus Users
Among antibiotic users, the frequency and percentage of those who were also on
Lactobacillus and those who were not are described in Table 4.8 and Table 4.9. In the
overall sample metronidazole (10,215 [28.64%]) and fluoroquinolones (9,532 [26.72%]),
and 1st generation cephalosporins (8,883 [24.90%]) were the most commonly prescribed
antibiotics. Other sulfonamides, tetracyclines, penicillinase-resistant penicillins were the
least commonly prescribed antibiotics. After applying the weights (Table 4.9 and Figure
4.10) 1st generation cephalosporins (370,000 [26.54%]), fluoroquinolones (250,000
[18.16%]), and Penicillins (130,000 [9.58%]) were the most commonly prescribed
antibiotics.
Before applying the analytical weights (Table 4.8 and Figure 4.9), among
Lactobacillus users, metronidazole (431 [89.79%]), fluoroquinolones (289 [60.21%]), 3rd
and 4th generation cephalosporins (171 [35.63%]), broad spectrum penicillins (167
[34.79%]), vancomycin (13; [27.08%]), and 1st generation cephalosporins (114 [23.75%])
were the most commonly prescribed antibiotics. The weighted frequencies (Table 4.9 and
Figure 4.10) among Lactobacillus users were: fluoroquinolones (1,630 [63.57%]),
metronidazole (1,294 [50.47%]), 1st generation cephalosporins (792 [30.88%]), 3rd and 4th
generation cephalosporins (753 [29.36%]), broad spectrum penicillins (711 [27.72%]),
macrolides (552; [21.54%]), and were the most commonly prescribed antibiotics.
Antibiotic prescribing trend in the Lactobacillus non-users was almost the same as
the overall sample. Generally, tetracyclines and other sulfonamides were the least
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prescribed antibiotics. Almost all Lactobacillus users (431 [89.79%]) used metronidazole
mainly for the CDI treatment.

Table 4.8 – Distribution of antibiotic use in the total sample and in Lactobacillus users
and non-users during total hospital stay [unweighted]

Antibiotics classes
Penicillins
Penicillinase-resistant
penicillins
Broad spectrum penicillins
1st gen. cephalosporins
2nd gen. cephalosporins
3rd & 4th gen. cephalosporins
Carbapenems
Aminoglycosides
Fluoroquinolones
Macrolides
Tetracyclines
Trimethoprim/Sulfamethoxazole
Other sulfonamides
Clindamycin
Vancomycin
Metronidazole
Miscellaneous

Overall
No.
%
3,644 10.22
550 1.54
4,337
8,883
1,583
5,327
2,059
3,530
9,532
2,467
420
2,423
199
2,064
1,068
10,215
2,951

12.16
24.90
4.44
14.93
5.77
9.90
26.72
6.92
1.18
6.79
0.56
5.79
3.03
28.64
8.27

Users
No.
%
71 14.79
23 4.79

Non-users
No.
%
3,573 10.15
527 1.50

167
114
19
171
80
82
289
85
10
63
0
29
130
431
91

4,170
8,769
1,564
5,156
1,979
3,448
9,243
2,382
410
2,360
199
2,035
1,198
9,784
2,860

34.79
23.75
3.96
35.63
16.67
17.08
60.21
17.71
2.08
13.13
0.00
6.04
27.08
89.79
18.96

11.85
24.92
4.44
14.65
5.62
9.80
26.27
6.77
1.17
6.71
0.57
5.78
3.36
27.80
8.13

N: Number of users in each class of antibiotics; %: Percentage of users of each class of antibiotics to the total
number of patients in the category.
Note: Percentage do not sum to 100 because patients may receive more than one class of antibiotics. An
index for detail list of all antibiotics is provided in the appendix (A).
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Table 4.9 – Distribution of antibiotic use in the total sample and in Lactobacillus users
and non-users during total hospital stay [weighted]

Antibiotics classes
Penicillins
Penicillinase-resistant penicillins*
Broad spectrum penicillins*
1st gen. cephalosporins
2nd gen. cephalosporins
3rd & 4th gen. cephalosporins*
Carbapenems*
Aminoglycosides*
Fluoroquinolones*
Macrolides*
Tetracyclines
Trimethoprim/Sulfamethoxazole*
Other sulfonamides
Clindamycin
Vancomycin*
Metronidazole*
Miscellaneous*

Overall
No. %
130,000 9.58
16,000 1.18
92,000 6.62
370,000 26.54
66,000 4.74
120,000 8.69
28,000 2.03
110,000 7.61
250,000 18.16
72,000 5.15
13,000 0.96
60,000 4.34
3858 0.28
73,000 5.24
2413 0.17
85,000 6.15
80,000 5.77

Users
No. %
375 14.63
222 8.65
711 27.72
792 30.88
218 8.52
753 29.36
428 16.68
453 17.67
1,630 63.57
552 21.54
99 3.86
370 14.41
0 0.00
128 4.98
338 13.17
1,294 50.47
596 23.25

Non-users
No. %
130,000 9.58
16,000 1.17
91,000 6.58
370,000 26.53
66,000 4.74
120,000 8.65
28,000 2.00
110,000 7.60
250,000 18.07
71,000 5.12
13,000 0.95
60,000 4.33
3858 0.28
73,000 5.24
2076 0.15
84,000 6.07
80,000 5.74

N: Number of users in each class of antibiotics; %: Percentage of users of each class of antibiotics to the total
number of patients in the category.
Note: Percentage do not sum to 100 because patients may receive more than one class of antibiotics. An
index for detail list of all antibiotics is provided in the appendix (A).
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Distribution of Antibiotic Use and CDI status
Among antibiotic users, the frequency and percentage of non-CDI, non-nosocomial
CDI, and nosocomial CDI patients are described in Table 4.10 and Table 4.11.
Antibacterial usage in the non-CDI group was mostly1st generation cephalosporin (7,086
[26.54%]) and fluoroquinolones (4,746 [17.77%]) Vancomycin and tetracyclines were the
least commonly prescribed antibiotics (Table 4.10 and Figure 4.10).
Before weighting (Table 4.10), metronidazole (4,227 [95.46%]), fluoroquinolones
(2,107 [47.58%]), 3rd & 4th generation cephalosporins (1,214 [27.42%]), broad spectrum
penicillins (1,022 [23.08%]), and vancomycin (715 [16.15%]) were the most commonly
prescribed antibiotics among non-nosocomial CDI cases. After applying the weight (Table
4.11), the same antibiotics were most commonly prescribed. Other sulfonamides,
penicillinase-resistant penicillins, and tetracyclines were the least prescribed antibiotics.
In the nosocomial CDI patients before weighting (Table 4.10), metronidazole
(4,485 [98.79%]), fluoroquinolones (2,679 [59.01%]), 3rd & 4th generation cephalosporins
(1,830 [40.31%]), broad spectrum penicillins (1,552 [34.19%]), and 1st generation
cephalosporins (1,311 [28.88%]) were most commonly prescribed antibiotics. After
applying the weight (Table 4.11), the same antibiotics were most commonly prescribed.
Tetracyclines and other sulfonamides were the least prescribed antibiotics.
Generally tetracyclines and other sulfonamides were the least prescribed
antibiotics. Almost all CDI cases used metronidazole, with (4,485 [98.59%]) of
nosocomial cases and (4,227 [5.46%]) of non-nosocomial cases using the agent. This was
most likely for CDI treatment.
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Table 4.10– Distribution of antibiotic use in the non-CDI, non-nosocomial CDI, and
nosocomial CDI patients [unweighted]

Antibiotics classes
Penicillins
Penicillinase-resistant penicillins
Broad spectrum penicillins
1st gen. cephalosporins
2nd gen. cephalosporins
3rd & 4th gen. cephalosporins
Carbapenems
Aminoglycosides
Fluoroquinolones
Macrolides
Tetracyclines
Trimethoprim/Sulfamethoxazole
Other sulfonamides
Clindamycin
Vancomycin
Metronidazole
Miscellaneous

Non-CDI
No.
%
2,449
9.17
325
1.22
1,763
6.60
7,086
26.54
1,149
4.30
2,283
8.55
570
2.13
59.01
7.80
4,746
17.77
1,415
5.30
241
0.90
1,139
4.27
95
0.36
1,361
5.10
27
0.10
1,503
5.63
1,588
5.95

Non-nosocomial
No.
%
477
10.77
65
1.47
1,022
23.08
486
10.98
109
2.46
1,214
27.42
519
11.72
532
12.01
2,107
47.58
423
9.55
77
1.74
511
11.54
36
0.81
214
4.83
715
16.15
4,227
95.46
498
11.25

Nosocomial
No.
%
718
15.81
160
3.52
1,552
34.19
1,311
28.88
325
7.16
1,830
40.31
970
21.37
915
20.15
2,679
59.01
629
13.85
102
2.25
773
17.03
68
1.50
489
10.77
456
10.04
4,485
98.79
865
19.05

N: Number of users in each class of antibiotics; %: Percentage of users of each class of antibiotics to the total
number of patients in the category.
Note: Percentage do not sum to 100 because patients may receive more than one class of antibiotics.
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Table 4.11– Distribution of antibiotic use in the non-CDI, non-nosocomial CDI, and
nosocomial CDI patients [weighted]

Antibiotics classes
Penicillins*
Penicillinase-resistant penicillins*
Broad spectrum penicillins*
1st gen. cephalosporins*
2nd gen. cephalosporins*
3rd & 4th gen. cephalosporins*
Carbapenems*
Aminoglycosides*
Fluoroquinolones*
Macrolides*
Tetracyclines*
Trimethoprim/Sulfamethoxazole*
Other sulfonamides*
Clindamycin*
Vancomycin*
Metronidazole*
Miscellaneous*

Non-CDI
No.
%
130,000 9.56
16,000
1.17
89,000
6.47
370,000 26.58
65,000
4.74
120,000 8.52
27,000
1.93
100,000 7.56
250,000 17.93
70,000
5.11
13,000
0.95
59,000
4.28
3754
0.27
72,000
5.23
1242
0.09
77,000
5.56
79,000
5.71

Non-nosocomial
No.
%
477
10.77
65
1.47
1,022
23.08
486
10.98
109
2.46
1,214
27.42
519
11.72
532
12.01
2,107
47.58
423
9.55
77
1.74
511
11.54
36
0.81
214
4.83
715
16.15
4,227
95.46
498
11.25

Nosocomial
No.
%
718
15.81
160
3.52
1,552 34.19
1,311 28.88
325
7.16
1,830 40.31
970
21.37
915
20.15
2,679 59.01
629
13.85
102
2.25
773
17.03
68
1.50
489
10.77
456
10.04
4,485 98.79
865
19.05

N: Number of users in each class of antibiotics; %: Percentage of users of each class of antibiotics to the total
number of patients in the category.
Note: Percentage do not sum to 100 because patients may receive more than one class of antibiotics.
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Description of Lactobacillus and Antibiotic Initiation Dates
Table 4.12 and Figure 4.9 show the description of the day on which Lactobacillus
was initiated with respect to antibiotic initiation dates among non-CDI, non-nosocomial
CDI, and nosocomial CDI patients. Over half of the non-CDI patients used Lactobacillus
five or more days after initiation of antibiotic therapy and (11 [30.56%]) started
Lactobacillus on or before the same day antibiotics were initiated. Similar to the non-CDI
group, the majority of non-nosocomial CDI patients started Lactobacillus five or more
days after antibiotic therapy was initiated; (86 [42.36%]). Also, the number of those who
used it on the same day or one day after antibiotic therapy was initiated was relatively high
at 36 (17.73%) and 25 (12.33%), respectively. In nosocomial CDI cases the majority (151
[80.32%]) started Lactobacillus five or more days after antibiotic therapy was initiated. In
general, Lactobacillus was mostly initiated five days or more after antibiotic therapy was
initiated (256 [59.95%]) or at the same day antibiotic therapy was initiated (59 [13.82%]).
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Table 4.12 – Description of the day Lactobacillus was initiated with respect to
antibiotic initiation date

Initiation of
antibiotic
therapy
Before*
Same day
One day after
Two days after
Three days after
Four days after
Five or more
days after

No CDI
(n=36)
No. (%)
5 (13.89)
6 (16.67)
2 (5.56)
0 (0.00)
1 (2.78)
3 (8.33)
19 (52.77)

Non-nosocomial
CDI
(n= 203)
No. (%)
15 (7.39)
36 (17.73)
25 (12.33)
13 (6.40)
16 (7.88)
12 (5.91)
86 (42.36)

Nosocomial
CDI
(n=188)
No. (%)
9 (4.79)
17 (9.04)
3 (1.60)
2 (1.06)
4 (2.13)
2 (1.06)
151 (80.32)

Total
(n= 427)
No. (%)
29 (6.79)
59 (13.82)
30 (7.03)
15 (3.51)
21 (4.92)
17 (3.98)
256 (59.95)

CDI: Clostridium difficile infection.
*Lactobacillus has been initiated before antibiotics therapy was initiated.
Note: Only patients who used the Lactobacillus were included in this table. Total number of patients in this
table is less than total Lactobacillus users since 53 patients used Lactobacillus but not antibiotics.
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Figure 4.9 – Number of days between initiation of Lactobacillus and the start dates of
antibiotics in overall sample
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Description of Lactobacillus and CDI Treatment Initiation Dates
Table 4.13 and Figure 4.10 show the description of the day Lactobacillus was
initiated with respect to CDI treatment (metronidazole or vancomycin) initiation dates
among non-nosocomial and nosocomial CDI cases. Among the non-nosocomial cases, the
majority started Lactobacillus five or more days after CDI treatment was initiated (95
[40.08%]). Also, those who started Lactobacillus on the same day or one day after CDI
treatment was initiated were relatively high at (61 [25.74%]) and (27 [11.39%]),
respectively. In the nosocomial CDI cases, the majority started Lactobacillus either before
(4; [20.79%]) or on the same day (42 [20.79%]) that CDI treatment was initiated. Also, the
percentage of those who started it five days or more after CDI treatment was initiated was
high; (76 [37.62%]). In general, Lactobacillus was mostly initiated five days or more after
CDI treatment was initiated (171 [38.95%]) or on the same day CDI treatment was
imitated (103 [23.46%]).
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Table 4.13 – Description of the day Lactobacillus was initiated with respect to CDI
treatment initiation date

Initiation of CDI
treatment
Before*
Same day
One day after
Two days after
Three days after
Four days after
Five or more days after

Non-nosocomial
CDI (n= 237)
No. (%)
15 (6.33)
61 (25.74)
27 (11.39)
19 (8.02)
12 (5.06)
8 (3.38)
95 (40.08)

Nosocomial CDI
(n= 202)
No. (%)
42 (20.79)
42 (20.79)
20 (9.90)
8 (3.96)
7 (3.47)
7 (3.47)
76 (37.62)

Total
(n= 439)
No. (%)
57 (12.98)
103 (23.46)
47 (10.71)
27 (6.15)
19 (4.33)
15 (3.42)
171 (38.95)

CDI: Clostridium difficile infection.
*Lactobacillus has been initiated before antibiotics therapy was initiated.
Note: Only CDI patients who used the Lactobacillus were included in this table. Total number of patients in
this table is less than Lactobacillus users since 39 patients who used Lactobacillus did not develop CDI.
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Figure 4.10 – Number of days between initiation of Lactobacillus and the start dates
of CDI treatment in the cases
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Crude Analysis of the Relationship Between Lactobacillus and CDI outcomes
The crude analysis of the relationship between the use of Lactobacillus and the
outcomes of interest in nosocomial CDI patients is shown in Table 4.11. The crude
analysis showed a significant relationship between Lactobacillus and post CDI diagnosis
length of stay (β = 8.643; 95% CI 5.744 to 11.542; P < 0.001). Use of Lactobacillus is
associated with an increase in post-CDI-diagnosis length of stay by approximately eight
days. The crude analysis showed a significant protective effect of Lactobacillus use of the
switch rate of CDI treatment (OR= 0.159; 95% CI 0.037 to 0.684; P = 0.014). Those who
used Lactobacillus were about 6 times less likely to switch CDI therapy than non-users.
There was no significant relationship between Lactobacillus use and readmission for CDI
or mortality.

Table 4.14 – The crude relationships between CDI related outcomes and the use of
Lactobacillus
Outcomes
Estimatea (SE)
P-value
95 % CI
Post diagnosis length of stay
8.643 (1.479)
< 0.001 (5.744, 11.542)
Switch rateb
0.159 (0.118)
0.014
(0.037, 0.684)
Readmission
1.310 (0.229)
0.124
(0.930, 1.845)
Mortality
0.946 (0.223)
0.822
(0.584, 1.533)
a

Estimate for length of stay is regression coefficient and others are odds ratios; bOnly patients who used
Lactobacillus after CDI diagnosis were considered (440 patients).
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Adjusted Analysis of the Relationship Between Lactobacillus and CDI Outcomes
The adjusted analysis of the relationship between Lactobacillus and the outcomes
of interest in nosocomial CDI patients are shown in Tables 4.12 and 4.13. After adjusting
for all available potential confounders in a logistic regression model, Lactobacillus use was
still significantly associated with an increase in post-CDI-diagnosis length of stay (β
=5.672; 95% CI 3.183 to 8.161; P < 0.001). The strength of the association, however, was
reduced when compared to the crude analysis (from 8.643 days to 5.672 days). After
adjustment, Lactobacillus use increases the post-diagnosis length of stay by about 5 days.
For the assessment of the adjusted relationship between Lactobacillus use and mortality,
severity of illness was re-categorized to two categories (minor/moderate, major/extreme)
because of large differences in patients in those groups. After adjustment, Lactobacillus
use was still significantly associated with a reduction in the likelihood of switching CDI
treatment (OR= 0.166; 95% CI 0.037 to 0.740; P = 0.019). There was not a large
difference in the strength of the association the crude and adjusted analysis. Lactobacillus
use was not significantly associated with readmission for CDI (OR= 1.376; 95% CI 0.970
to 1.951; P 0.074) after adjusting for potential confounders in a logistic regression model.
As in the crude relationship, Lactobacillus use was not significantly associated with
mortality (OR= 0.736; 95% CI 0.510 to 1.063; P = 0.103) after adjusting for all available
potential confounders in a logistic regression model. Detailed tables with the output of the
four regression models used in this analysis are included in Appendix A
.
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Table 4.15 – Adjusted relationship between Lactobacillus use and length of stay and
likelihood of switching CDI treatment

Independent variables
Lactobacillus use
Age (years)
Sex
Race:
Caucasian (Ref.)
African American
Other
Transfer from outside
hospital
Switched CDI treatment
Severity of illness:
Minor/Moderate (Ref.)
Major
Extreme
ICU-days
Charlson score
Mortality
Constant

Length of stay
β (95% CI)
P-value
5.672
< 0.001
(3.183,8.161)
-0.071
< 0.001
(-0.10, -0.04)
-0.080
0.882
(-1.13, 0.97)
0.350
—
0.624
(-0.754, 2.002)
1.010
(-0.509, 2.529)
1.532
0.389
(-1.952, 5.016)
0.260
0.926
(-5.235, 5.755)
< 0.001
—
1.935
(0.190, 3.679)
6.809
(5.111, 8.506)
0.679
< 0.001
(0.642, 0.717)
0.087
0.420
(-0.124, 0.298)
-0.009
0.993
(-1.844, 1.826)
8.368
0.006
(2.459, 14.277)

Switch rate
OR (95% CI) P-value
0.166
0.019
(0.037, 0.740)
1.002
0.841
(0.983, 1.022)
1.412
0.313
(0.723, 2.757)
0.054
—
4.097
(0.968, 17.335)
0.938
(0.403, 2.181)
0.953
0.962
(0.127, 7.151)
N/A
N/A
0.406
—
0.562
(0.159, 1.990)
0.565
(0.162, 1.972)
1.015
(0.985, 1.046)
1.029
(0.897, 1.179)
0.839
(0.280, 2.513)
N/A

0.320
0.686
0.754

OR: Odds ratio; β: Regression coefficient; CI: Confidence interval; SOI: Severity of illness; ICU-days:
Number of intensive care unit days; N/A: not applicable.
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Table 4.16 – Adjusted relationship between Lactobacillus use and readmission and
mortality

Independent variables
Lactobacillus use
Age (years)
Sex
Race:
Caucasian (Ref.)
African American
Other
Transfer from outside
hospital
Switched CDI treatment
Severity of illness:
Minor/Moderate (Ref.)
Major
Extreme
ICU-days
Charlson score
Mortality
Constant

Readmission
OR (95% CI)
P-value
1.376
0.074
(0.970, 1.951)
0.998
0.469
(0.994, 1.003)
0.865
0.072
(0.738, 1.013)
0.287
—
1.086
(0.887, 1.330)
0.870
(0.687, 1.101)
0.601
0.118
(0.318, 1.138)
1.560
0.358
(0.605, 4.021)
0.591
—
1.062
(0.820, 1.375)
1.155
(0.899, 1.486)
0.985
< 0.001
(0.978, 0.993)
0.986
0.405
(0.955, 1.019)
0.393
< 0.001
(0.270, 0.571)
N/A

Mortality
OR (95% CI) P-value
0.736
0.103
(0.510, 1.063)
1.019
<0.001
(1.014, 1.024)
0.910
0.234
(0.780, 1.063)
0.2421
—
0.878
(0.717, 1.075)
0.851
(0.669, 1.082)
1.590
0.016
(1.089, 2.321)
0.732
0.297
(0.408, 1.315)
<0.001
—
N/A*
16.525
(7.364, 37.081)
1.032
(1.027, 1.036)
1.119
(1.089, 1.150)
N/A

< 0.001
< 0.001
N/A

N/A

OR: Odds ratio; CI: Confidence interval; SOI: Severity of illness; ICU-days: Number of intensive care unit
days; N/A: not applicable.
*Severity of illness was re-categorized to two categories (minor/moderate, major/extreme) to reduce the
variability.
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CHAPTER 5: DISCUSSION
Incidence and severity of CDI has been continuously increasing in the United
States over the last decade.47 This is a debilitating illness with a high cost, especially
among recurrent CDI cases. The literature shows some evidence of the beneficial effects of
probiotics in treatment of CDI through its ability to restore the balance in the normal flora
that have been disrupted by the prior use of antibiotics
This retrospective cohort study gives a detailed description of the characteristics of
Lactobacillus users and non-users among CDI cases and non-cases. This is the first study
to describe in detail probiotics users. This study found that almost all Lactobacillus users
were patients with CDI indicating that the use of Lactobacillus may be mainly for
treatment of CDI and not prevention of it. Also most all Lactobacillus users (89.16%) had
either major or extreme severity of illness unlike the non-users who had mainly minor or
moderate severity of illness. This also supports the conclusion that Lactobacillus is only
prescribed for severe cases of CDI. As the severity of illness increased, the frequency of
Lactobacillus use increased. The opposite relationship was true for the severity of illness
and number of Lactobacillus non-users. Additionally, it was found that users were
significantly different from non-users in age, number of antibiotics received, mortality,
readmission, and length of stay. Users were significantly older (mean age = 61.09; 95% CI
59.46 to 62.71) than non users (mean age = 53.78; 95% CI53.85 to 53.98). As the number
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of antibiotics received increased, the frequency of Lactobacillus use increased. The
opposite relationship was true for the number of antibiotics received and number of
Lactobacillus non-users. Readmission and length of stay were significantly higher for
Lactobacillus users than non-users. All of these risk factors are associated with CDI and
consequently with the use of Lactobacillus and are consistent with the reported risk factors
in the literature12, 57, 58 In both users and non-users, IDC-9-CM code (008.45) for CDI was
among the top diagnosis codes in general because the sample was selected based on that
code.
This study found that certain antibiotic classes (metronidazole, fluoroquinolones,
3rd and 4th generation cephalosporins, broad spectrum penicillins, vancomycin, and 1st
generation cephalosporins) were used most frequently by Lactobacillus users. This
supports the published literature that describes classes of antibiotics associated with CDI.52,
53, 56

That could introduce bias in the ability of determining the effects of Lactobacillus on

CDI related outcomes. The results are also consistent with prior research findings that
hospital-acquired CDI is related to age, time spent in the hospital (before the diagnosis
date), use of proton pump inhibitors, and gastrointestinal disease.
Analytical weights were used in the analysis to account for the random sampling
approach in the original risk factor study. These weights allowed each individual to be
representative of the actual number of patients in the UHC population. For that reason the
there were large differences between weighted Lactobacillus users who were non-CDI
patients (n = 2,125 [82.88%]) and unweighted Lactobacillus users non-CDI patients (41
[8.54%])
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There was evidence of a statistically significant relationship between Lactobacillus
use and post-CDI-diagnosis length of stay. Lactobacillus users were expected to have
longer length of stay than non-users. However, the direction of these relationships was
unexpected. This could be explained by the fact most of CDI cases were older and more
severely ill than non-CDI patients. All of these factors may have driven the relationship in
the unexpected direction even after accounting for it in a regression model. Also, there was
a statistically significant relationship between Lactobacillus use and switch rate of CDI
treatment. Non-users were about 6 times more likely to switch their CDI treatment than
users. Lactobacillus use was not significantly associated with either readmission for CDI
or mortality. Switch rate of CDI treatment was selected as an outcome variable because it
could be used as a marker of CDI treatment failure. Patients who are cured on oral
metronidazole usually switch to oral vancomycin. From the descriptive part of this study, it
is clear that Lactobacillus was mainly prescribed for the sicker patients as a last resort
treatment. However, literature shows that probiotics are better for prevention of CDI than
treatment. This fact may also have reduced the ability of detecting the true relationship and
may have driven it in the unexpected direction.
The large sample size used in this study theoretically allowed for a high power to
detect the association between Lactobacillus use and the outcome variables of interest.
Given the significant differences between Lactobacillus users and non-users, more
complex models would need to be conducted with an observational data to estimate more
appropriately the relationship between Lactobacillus use and the CDI-related outcomes.
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Limitations
Even though the data used in this study came from different hospitals around the
nation, there is a considerable variation in the number of participating hospitals each year.
That variability may have introduced bias in that they may have had greatly different
characteristics with regards to antibiotic and Lactobacillus use. Elimination of these
hospitals would have greatly reduced the sample size. Considering that all the hospitals in
this study were from academic healthcare centers, the finding may not be generalizable to
other non-academic hospitals.
C. difficile is one of most commonly indentified causes of nosocomial diarrhea. It is
certain that infection control practices such as gloves, hand washing, and disinfectant use
may affect the rates of infection. The data used in this study do not include such
information, and therefore it was not accounted for in the regression models used in the
analysis.
Another potential limitation is the lack of laboratory information that might help in
confirming the diagnosis of CDI. The CRM database was developed for administrative
purposes and does not include laboratory results. Because of that limitation confirmation of
ICD-9-CM codes with laboratory assay results for CDI was not done. Instead, cases were
indentified based on the ICD-9-CM code (008.45) for CDI using a recently developed and
validated definition by Schmiedeskamp et al.77 Another potential limitation is that the
validity of the drug usage data in the UHC CRM database has been examined in only one
participating hospital.
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Lactobacillus users and non-users were very different since they were not matched
to each other. Instead, CDI cases and controls were matched on the hospital and quarter in
which they were discharged. This variability between Lactobacillus users and non-users is
an issue for the analytical parts, but not really for the descriptive piece. In this study
Lactobacillus use was not classified as before or after-CDI-diagnosis since there was only
small number of patients who used it before-CDI-diagnosis. That did not allow assessment
of Lactobacillus use as a prevention therapy.
Another limitation is that the direction of switch of therapy was not measure.
Switching from metronidazole to vancomycin or vancomycin to metronidazole was
considered the same. However, that could have different meaning. Switching from
metronidazole to vancomycin represents treatment failure while switching from
vancomycin to metronidazole does not.

Future Directions
The descriptive findings from this study provide information on the general
characteristics of Lactobacillus users that could be used as a foundation for generating
hypothesis for future research in this field. The population of this study was adult
hospitalized patients. A future descriptive study on hospitalized children could be
conducted.
This study also attempted to identify the relationship between the use Lactobacillus
and several CDI related outcomes. Due to the large differences between CDI cases and the
controls the true relationships were difficult to identify. To overcome this problem,
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modification in the design or the analysis of the study should be considered in the future
studies. Matching on more variables in a retrospective or a prospective cohort or case
control studies will reduce the variability and might better identify the true relationships
between Lactobacillus use and various CDI related outcomes. If the there were significant
relationship after a prospective study, a randomized clinical trial with sufficient sample
size should be conducted for more accurate assessment of the true relationship. In addition,
propensity score method could account for more variability between Lactobacillus users
and non-users.

Conclusions
Lactobacillus users and non-users were different in most characteristics.
Lactobacillus use by CDI cases was high and mainly started on the same day or before
initiation of antibiotics. Lactobacillus use was associated with increased length of stay and
switch of CDI therapy. Although this study describes the types of patients who are
receiving Lactobacillus, the true association between Lactobacillus use and CDI-related
outcomes remains unclear and further research is needed.
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Table A.1 – Adjusted relationship between Lactobacillus use and post CDI diagnosis
post length of stay

Independent variables
Lactobacillus use
Age (year)
Sex
Race:
Caucasian (Ref.)
African American
Other
Transfer from outside
hospital
Switched CDI treatment
Severity of illness:
Minor/Moderate
(Ref.)
Major
Extreme
ICU-days
Charlson score
Mortality
Constant

β
5.672
-0.071
-0.080

SE
1.270
0.016
0.535

t
4.47
-4.42
-0.15

—
0.624
1.010

—
0.703
0.775

—
0.89
1.30

1.532
0.260

1.777
2.803

0.86
0.09

—

—

—

1.935
6.809
0.679
0.087
-0.009
8.368

0.890 2.17
0.866 7.86
0.019 35.57
0.108 0.81
0.936 -0.01
3.014 2.78

P-value
< 0.001
< 0.001
0.882
0.350

0.389
0.926
< 0.001

< 0.001
0.420
0.993
0.006

95 % Confidence
Intervals
Lower
Upper
3.183
8.161
-0.102
-0.039
-1.129
0.970
—
-0.754
-0.509

—
2.002
2.529

-1.952
-5.235

5.016
5.755

—

—

0.190
5.111
0.642
-0.124
-1.844
2.459

3.679
8.506
0.717
0.298
1.826
14.277

No. observations = 4,345; F (12, 4,332) = 148.05; p < 0.001; R2 = 0.291; Adjusted R2 = 0.289
β: Regression coefficient; SE: Standard error; ICU-days: Number of intensive care unit days; CDI: C.
difficile infection.
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Table A.2 – Adjusted relationship between Lactobacillus use and the likelihood of
switching CDI treatment

Independent variables
Lactobacillus use
Age (year)
Sex
Race:
Caucasian (Ref.)
AfricanAmerican
Other
Transfer from outside
hospital
Severity of illness:
Minor/Moderate
(Ref.)
Major
Extreme
ICU-days
Charlson score
Mortality

OR
SE
0.166 0.126
1.002 0.010
1.412 0.482

Z
-2.350
0.200
1.010

—
—
4.097 3.015
0.938 0.404

—
1.920
-0.150

0.953 0.980

-0.050

P-value
0.019
0.841
0.313
0.054

0.962
0.406

95 % Confidence
Intervals
Lower
Upper
0.037
0.740
0.983
1.022
0.723
2.757
—
0.968
0.403

—
17.335
2.181

0.127

7.151

—

—

—

—

—

0.562
0.565
1.015
1.029
0.839

0.363
0.360
0.016
0.072
0.470

-0.890
-0.900
0.990
0.400
-0.310

0.159
0.162
0.985
0.897
0.280

1.990
1.972
1.046
1.179
2.513

0.320
0.686
0.754

No. observations = 4,186; Log likelihood = -209.99; Likelihood ratio χ2 = 13.01; p = 0.292
OR: Odds ratio;CI: Confidence interval; SE: Standard error; ICU-days: Number of intensive care unit days;
CDI: C. difficile infection.
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Table A.3 – Adjusted relationship between Lactobacillus use and readmission

Independent variables
Lactobacillus use
Age (year)
Sex
Race:
Caucasian (Ref.)
African American
Other
Transfer from outside
hospital
Switched CDI treatment
Severity of illness:
Minor/Moderate
(Ref.)
Major
Extreme
ICU-days
Charlson score
Mortality

OR
1.376
0.998
0.865

SE
Z
0.245 1.79
0.002 -0.72
0.070 -1.80

—
1.086
0.870
0.601

—
—
0.112 0.80
0.105 -1.16
0.196 -1.56

1.560

0.754

0.92

—

—

—

1.062
1.155
0.985
0.986
0.393

0.140 0.46
0.148 1.13
0.004 -3.91
0.016 -0.83
0.075 -4.90

P-value
0.074
0.469
0.072
0.287

0.118
0.358
0.436

< 0.001
0.405
< 0.001

95 % Confidence
Intervals
Lower
Upper
0.970
1.951
0.994
1.003
0.738
1.013
—
0.887
0.687
0.318

—
1.330
1.101
1.138

0.605

4.021

—

—

0.820
0.899
0.978
0.955
0.270

1.375
1.486
0.993
1.019
0.571

No. observations = 4,345; Log likelihood = -2020.44; Likelihood ratio χ2 = 67.33; p < 0.001
OR: Odds ratio; CI: Confidence interval; SE: Standard error; ICU-days: Number of intensive care unit days;
CDI: C. difficile infection.
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Table A.4 – Adjusted relationship between Lactobacillus use and mortality

Independent variables
Lactobacillus use
Age (year)
Sex
Race:
Caucasian (Ref.)
African American
Other
Transfer from outside
hospital
Switched CDI treatment
Severity of illness:
Minor/Moderate
(Ref.)
Major /Extreme
ICU-days
Charlson score

OR
0.736
1.019
0.910

SE
Z
0.138 -1.63
0.003 7.72
0.072 -1.19

—
0.878
0.851
1.590

—
—
0.091 -1.26
0.104 -1.32
0.307 2.40

0.732

0.219 -1.04

—

—

P-value
0.103
<0.001
0.234
0.2421

0.016
0.297
<0.001

—

16.525 6.814 6.80
1.032 0.002 13.68
1.119 0.016 8.00

<0.001
<0.001

95 % Confidence
Intervals
Lower
Upper
0.510
1.063
1.014
1.024
0.780
1.063
—
0.717
0.669
1.089

—
1.075
1.082
2.321

0.408

1.315

—

—

7.364
1.027
1.089

37.081
1.036
1.150

No. observations = 4,345; Log likelihood = -2020.44; Likelihood ratio χ2 = 67.33; p < 0.001
OR: Odds ratio; CI: Confidence interval; SE: Standard error; ICU-days: Number of intensive care unit days;
CDI: C. difficile infection.
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